UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset

Elkhalifa, M; Orbai, A-M; Magder, LS; Petri, M; Alarcon, GS; Gordon, C; Merrill, J; ... Franks, AG; + view all (2021) Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus , 30 (8) pp. 1283-1288. 10.1177/09612033211014248. Green open access

[thumbnail of Isenberg_Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset_AAM.pdf]
Preview
Text
Isenberg_Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset_AAM.pdf - Accepted Version

Download (173kB) | Preview

Abstract

OBJECTIVE: Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic Lupus International Collaborating Clinics (SLICC) criteria. We aimed to evaluate the prevalence of anti-beta 2-glycoprotein I IgA in SLE versus other rheumatic diseases. In addition, we examined the association between anti-beta 2 glycoprotein I IgA and disease manifestations in SLE. METHODS: The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations. RESULTS: The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI: 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant. CONCLUSION: We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes.

Type: Article
Title: Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset
Open access status: An open access version is available from UCL Discovery
DOI: 10.1177/09612033211014248
Publisher version: https://doi.org/10.1177%2F09612033211014248
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions.
Keywords: Systemic lupus erythematosus, antiphospholipid antibodies, classification criteria, anti-beta 2 glycoprotein IgA
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation
URI: https://discovery.ucl.ac.uk/id/eprint/10131180
Downloads since deposit
239Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item